DB:SMIF

Stock Analysis Report

China Medical & HealthCare Group

Executive Summary

China Medical & HealthCare Group Limited, an investment holding company, primarily operates hospitals.


Snowflake Analysis

Imperfect balance sheet with questionable track record.

Share Price & News

How has China Medical & HealthCare Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SMIF's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

SMIF

3.0%

DE Healthcare

2.2%

DE Market


1 Year Return

-30.5%

SMIF

-25.9%

DE Healthcare

-17.2%

DE Market

Return vs Industry: SMIF underperformed the German Healthcare industry which returned -25.6% over the past year.

Return vs Market: SMIF underperformed the German Market which returned -17.5% over the past year.


Shareholder returns

SMIFIndustryMarket
7 Day0%3.0%2.2%
30 Day-12.0%-15.4%-15.7%
90 Day-14.3%-20.2%-24.0%
1 Year-30.5%-30.5%-24.6%-25.9%-14.9%-17.2%
3 Year-70.7%-70.7%-40.4%-42.5%-16.4%-23.3%
5 Year-34.7%-34.7%-27.6%-31.6%-16.5%-27.8%

Price Volatility Vs. Market

How volatile is China Medical & HealthCare Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is China Medical & HealthCare Group undervalued compared to its fair value and its price relative to the market?

54.79x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SMIF's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SMIF's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SMIF is poor value based on its PE Ratio (54.8x) compared to the Healthcare industry average (27.5x).

PE vs Market: SMIF is poor value based on its PE Ratio (54.8x) compared to the German market (16.3x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SMIF's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SMIF is good value based on its PB Ratio (1.1x) compared to the DE Healthcare industry average (1.1x).


Next Steps

Future Growth

How is China Medical & HealthCare Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

9.4%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as China Medical & HealthCare Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has China Medical & HealthCare Group performed over the past 5 years?

-43.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SMIF has a large one-off gain of HK$19.9M impacting its June 30 2019 financial results.

Growing Profit Margin: SMIF became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: SMIF has become profitable over the past 5 years, growing earnings by -43.3% per year.

Accelerating Growth: SMIF has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: SMIF has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (26%).


Return on Equity

High ROE: SMIF's Return on Equity (2%) is considered low.


Next Steps

Financial Health

How is China Medical & HealthCare Group's financial position?


Financial Position Analysis

Short Term Liabilities: SMIF's short term assets (HK$1.1B) do not cover its short term liabilities (HK$1.2B).

Long Term Liabilities: SMIF's short term assets (HK$1.1B) exceed its long term liabilities (HK$266.4M).


Debt to Equity History and Analysis

Debt Level: SMIF's debt to equity ratio (44.5%) is considered high.

Reducing Debt: SMIF's debt to equity ratio has reduced from 127.9% to 44.5% over the past 5 years.


Balance Sheet

Inventory Level: SMIF has a high level of physical assets or inventory.

Debt Coverage by Assets: SMIF's debt is covered by short term assets (assets are 1.4x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SMIF is profitable, therefore cash runway is not a concern.

Forecast Cash Runway: Insufficient data to determine if SMIF has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is China Medical & HealthCare Group's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SMIF's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SMIF's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SMIF's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SMIF's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: SMIF is not paying a notable dividend for the German market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SMIF's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average board tenure


CEO

China Medical & HealthCare Group has no CEO, or we have no data on them.


Board Members

NamePositionTenureCompensationOwnership
Sok Un Chong
Deputy Chairman4.25yrsHK$473.00kno data
Muk Yin Kong
Executive Director17.83yrsHK$1.82mno data
Meibao Guo
Executive Director1.42yrsno datano data
Haiying Zhou
Executive Director1.25yrsno datano data
Peng Chong Wong
Non-Executive Director18yrsHK$1.82mno data
Lai Sum Yang
Independent Non-Executive Director1.25yrsno datano data
Xiaoning Xia
Independent Non-Executive Director3.25yrsHK$220.00kno data
Wing Kuen Wong
Independent Non-Executive Director1.25yrsno datano data
Jian Zhang
Independent Non-Executive Director13.42yrsHK$100.00kno data
Liye Zhou
Chairman1.25yrsno datano data

2.3yrs

Average Tenure

57.5yo

Average Age

Experienced Board: SMIF's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

China Medical & HealthCare Group Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: China Medical & HealthCare Group Limited
  • Ticker: SMIF
  • Exchange: DB
  • Founded:
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Market Cap: HK$1.911b
  • Listing Market Cap: HK$224.392m
  • Shares outstanding: 14.48b
  • Website: https://www.cmhg.com.hk

Number of Employees


Location

  • China Medical & HealthCare Group Limited
  • China Online Centre
  • 47th Floor
  • Wanchai
  • Hong Kong

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
383SEHK (The Stock Exchange of Hong Kong Ltd.)YesOrdinary SharesHKHKDJan 1992
SMIFDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJan 1992

Biography

China Medical & HealthCare Group Limited, an investment holding company, primarily operates hospitals. It operates through six segments: Healthcare, Eldercare, Property Development, Property Investment, Financial Services, and Securities Trading and Investments. The company is also involved in the property development of independent living units; and project management of health campus with a focus on elderly care and retirement community comprising elderly nursing homes, service apartments, and independent living units, as well as a shopping mall, retail shops, and club hall facilities. In addition, it develops and sells properties and land; leases residential and office properties; and provides money lending, financial and strategic investment, and healthcare services. Further, the company is involved in the medical equipment and related supplies. Additionally, it invests and trades in securities. The company operates in the People’s Republic of China and Hong Kong. It is also involved in the trading of securities listed in overseas exchange. The company was formerly known as COL Capital Limited and changed its name to China Medical & HealthCare Group Limited in February 2016. The company is headquartered in Wanchai, Hong Kong. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/31 21:13
End of Day Share Price2020/03/31 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.